首页> 美国卫生研究院文献>Cellular and Molecular Gastroenterology and Hepatology >Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx–DDB1 Interaction
【2h】

Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx–DDB1 Interaction

机译:通过靶向HBx–DDB1相互作用抑制硝唑尼特从cccDNA转录HBV

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background & AimsHepatitis B virus (HBV) infection is a major health concern worldwide. Although currently used nucleos(t)ide analogs efficiently inhibit viral replication, viral proteins transcribed from the episomal viral covalently closed circular DNA (cccDNA) minichromosome continue to be expressed long-term. Because high viral RNA or antigen loads may play a biological role during this chronicity, the elimination of viral products is an ultimate goal of HBV treatment. HBV regulatory protein X (HBx) was recently found to promote transcription of cccDNA with degradation of Smc5/6 through the interaction of HBx with the host protein DDB1. Here, this protein–protein interaction was considered as a new molecular target of HBV treatment.
机译:背景与目的乙型肝炎病毒(HBV)感染是全球主要的健康问题。尽管当前使用的核苷(核苷酸)类似物可有效抑制病毒复制,但从游离病毒共价闭合环状DNA(cccDNA)小染色体转录的病毒蛋白仍可长期表达。由于高病毒RNA或抗原载量可能在这种慢性病中起生物学作用,因此消除病毒产物是HBV治疗的最终目标。最近发现,HBV调节蛋白X(HBx)通过HBx与宿主蛋白DDB1的相互作用促进cccDNA的转录,同时Smc5 / 6降解。在这里,这种蛋白间相互作用被认为是HBV治疗的新分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号